Login to Your Account

Class act: Macrolide bid draws $22M in series A for antibacterials work

By Randy Osborne
Staff Writer

Wednesday, March 4, 2015

With $22 million in series A fuel and technology licensed from Harvard University, Macrolide Pharmaceuticals Inc. is "blowing out the class" of antibiotics after which the company is named "in a very rapid and efficient manner," explained CEO and co-founder Lawrence Miller.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription